Natco Pharma

Natco Pharma EBIT Margin

The EBIT Margin (Operating Margin) of Natco Pharma (NATCOPHARM.NS) as of Oct 24, 2026 is 37.45 %. In the previous year, EBIT Margin (Operating Margin) was 67.70 % — a change of -44.67% (lower).

EBIT Margin

37.45 %

YoY

-44.67%

Last updated:

EBIT Margin (Operating Margin) of Natco Pharma is 2026 37.45 % . EBIT Margin (Operating Margin) of Natco Pharma was 2025 67.70 % . It decreases by -44.67% lower compared to the previous year.

For Natco Pharma, the operating (EBIT) margin of 37.5% is up versus 35.6% a few years ago.

The Natco Pharma EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
51.49 INR
Jan 1, 2020
45.81 INR
Jan 1, 2021
45.28 INR
Jan 1, 2022
35.61 INR
Jan 1, 2023
55.61 INR
Jan 1, 2024
64.87 INR
Jan 1, 2025
67.70 INR
Jan 1, 2026
37.45 INR
The Natco Pharma EBIT Margin history
YEAREBIT MarginYoY
37.45 %-44.67%
67.70 %+4.36%
64.87 %+16.66%
55.61 %+56.16%
35.61 %-21.37%
45.28 %-1.15%
45.81 %-11.03%
51.49 %-11.07%
57.90 %+12.46%
51.49 %-0.88%
51.94 %-1.56%
52.76 %+96.06%
26.91 %+13,152.39%
0.20 %+12.64%
0.18 %-11.71%
0.20 %+2.51%
0.20 %+14.71%
0.17 %-14.29%
0.20 %-2.77%
0.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Natco Pharma Stock analysis

What does Natco Pharma do? Natco Pharma Ltd is an Indian pharmaceutical company that was founded in 1981. It is headquartered in Hyderabad, India and also operates branches in other parts of India and overseas. History Natco Pharma Ltd was founded by Dr. Devinder Pal Singh. The company started as a small generic drug manufacturing company but gradually expanded and today is one of the leading pharmaceutical companies in India. In the early 2000s, Natco Pharma Ltd entered the international market and has since conducted many important partnerships and acquisitions to expand its business. Business model Natco Pharma Ltd's business model focuses on the research, development, and manufacturing of drugs used in various therapeutic areas. The company primarily produces generics but also biosimilars and innovative products. Natco Pharma Ltd aims to provide affordable and accessible medications to patients in India and worldwide. Products and divisions Natco Pharma Ltd produces a wide range of medications divided into various divisions. The company's main divisions include oncology, hepatitis C, nephrology, neurology, cardiology, and anti-infectives. Natco Pharma Ltd also offers a range of biosimilars, including pegfilgrastim and trastuzumab, and has launched innovative products such as Natdac (daclatasvir) and Hepcinat LP (sofosbuvir and ledipasvir). The company also has a separate department for the production of active pharmaceutical ingredients (APIs) and has multiple manufacturing facilities in different parts of India certified by strict international quality standards (such as USFDA, UK-MHRA, and TGA). Activities Natco Pharma Ltd has been involved in several patent litigation cases to facilitate access to affordable generic medications. A significant example is the patented cancer drug Nexavar by Bayer. Natco Pharma Ltd won a long legal battle, allowing it to bring a cheaper version of the drug to the market. Natco Pharma Ltd has also built partnerships with other pharmaceutical companies to promote the distribution of its medications on a global level. One important collaboration of the company is with Mylan to manufacture affordable versions of HIV/AIDS medications for developing countries. Conclusion Natco Pharma Ltd is a strong example of a company that has been able to grow through quality, research, and affordable products. It has also been involved in several patent disputes to improve access to affordable medications. The wide range of medications and divisions shows that Natco Pharma Ltd is a significant player in the Indian and international market. Natco Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natco Pharma stock

EBIT Margin (Operating Margin) of Natco Pharma is 37.45 % in 2026.

EBIT Margin (Operating Margin) of Natco Pharma changed from 67.70 % to 37.45 %, representing a -44.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Natco Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Natco Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Natco Pharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Natco Pharma